Application of Risk Management Principles for Medical Devices

This CDRH Learn module explains U.S. FDA's thoughts on the application of risk management principles for medical devices. It provides important information on risk analysis tools and review of benefit-risk information, including concepts from ISO 13485:2019. To view more educational resources please visit https://www.fda.gov/training-and-cont....

Risk Basics for Medical Devices
▶︎

Risk Basics for Medical Devices

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
▶︎

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice

Is My Product A Medical Device
▶︎

Is My Product A Medical Device

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing
▶︎

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine
▶︎

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine

OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products
▶︎

OTP Town Hall: Best Practices for Preparing BLA Submissions for Cell and Gene Therapy Products

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
▶︎

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video
▶︎

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards
▶︎

AGDD 2025 | D1S01 - Product-Specific Guidance for Complex Products: From Research to Standards

FDA Direct: Combating Rare Diseases at the FDA
▶︎

FDA Direct: Combating Rare Diseases at the FDA

How is CDRH Structured?
▶︎

How is CDRH Structured?

FDA Grand Rounds - Pharmacovigilance in Practice: From Safety Signals to Regulatory Action
▶︎

FDA Grand Rounds - Pharmacovigilance in Practice: From Safety Signals to Regulatory Action

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel
▶︎

AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
▶︎

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers
▶︎

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers

Conversations on Cancer: Patient first = Project Facilitate
▶︎

Conversations on Cancer: Patient first = Project Facilitate

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel
▶︎

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel

VRBPAC -- May 28 Meeting
▶︎

VRBPAC -- May 28 Meeting

AGDD 2025 | D1S01 – Session 1: Q&A Discussion Panel
▶︎

AGDD 2025 | D1S01 – Session 1: Q&A Discussion Panel